Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 31, Number 5—May 2025
CME ACTIVITY - Synopsis

Features of Invasive Aspergillosis Caused by Aspergillus flavus, France, 2012–2018

Lise Bertin-Biasutto, Olivier Paccoud, Dea Garcia-Hermoso, Blandine Denis, Karine Boukris-Sitbon, Olivier Lortholary, Stéphane Bretagne, Maud Gits-Muselli, Raoul Herbrecht, Valérie Letscher-Bru, François Danion, Sophie Cassaing, Florent Morio, Céline Nourrisson, Marc Pihet, Milène Sasso, Guillaume Desoubeaux, Marie-Fleur Durieux, Julie Bonhomme, Elisabeth Chachaty, Taieb Chouaki, Nicole Desbois-Nogard, Alexandre Alanio1, Jean-Pierre Gangneux1, and Fanny LanternierComments to Author 
Author affiliation: Hopital Necker-Enfants Malades, Paris, France (L. Bertin-Biasutto, O. Paccoud, O. Lortholary, F. Lanternier); Université de Paris, Paris (L. Bertin-Biasutto, O. Lortholary, F. Lanternier); Institut Pasteur, Paris (D. Garcia-Hermoso, K. Boukris-Sitbon, O. Lortholary, S. Bretagne, A. Alanio, F. Lanternier); Hôpital Saint Louis, Paris (B. Denis, S. Bretagne, M. Gits-Muselli, A. Aliano); Institut de Cancérologie de Strasbourg, Strasbourg, France (R. Herbrecht); Hôpitaux Universitaires de Strasbourg, Strasbourg (V. Letscher-Bru, F. Danion); Toulouse University Hospital, Toulouse, France (S. Cassaing); Nantes University Hospital, Nantes, France (F. Morio); CHU Clermont-Ferrand, Clermont-Ferrand, France (C. Nourrisson); CHU d'Angers, Angers, France (M. Pihet); CHU Nîmes and Université de Montpellier, Nîmes, France (M. Sasso); Hôpital Bretonneau, Tours, France (G. Desoubeaux); Limoges University, Limoges, France (M.-F. Durieux); Unicaen Université Normandie, Caen, France (J. Bonhomme); Gustave Roussy, Villejuif, France (E. Chachaty); CHU Amiens-Picardie, Amiens, France (T. Chouaki); Inserm U1285, University of Lille, Lille, France (T. Chouaki); Centre Hospitalier Universitaire de Martinique, Fort-de-France, France (N. Desbois-Nogard); Université de Rennes, CHU Rennes, Rennes, France (J.-P. Gangneux); Rennes Teaching Hospital, Rennes (J.-P. Gangneux)

Main Article

Table 5

MICs of first-line antifungal drugs used for 46 cases of invasive aspergillosis caused by Aspergillus flavus, France, 2012–2018*

Antifungal drug Range, mg/L MIC50 MIC90
Voriconazole 0.125–1 0.5 1
Isavuconazole 0.25–2 0.5 1
Itraconazole 0.06–0.5 0.125 0.25
Posaconazole <0.015–0.25 0.125 0.25
Liposomal amphotericin B 0.5 to >4 1 4
Caspofungin 0.125–0.5 0.25 0.5
Micafungin 0.007–0.03 0.007 0.015

*Values according to European Committee on Antimicrobial Susceptibility Testing broth microdilution method (https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_EDef_9.4_method_for_susceptibility_testing_of_moulds.pdf). MIC50, MIC that inhibited 50% of tested microorganisms; MIC90, that inhibited 90% of tested microorganisms.

Main Article

1These authors contributed equally contributed to this article.

Page created: March 19, 2025
Page updated: April 29, 2025
Page reviewed: April 29, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external